Cancer clinical trials in the region Grand Est
289 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Lung cancer
#NCT05692999
#2023-503481-23-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
28 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3
Lung cancer
#NCT06170788
#2023-503376-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Merck Sharp & Dohme LLC
Phase 3
Lung cancer
#NCT06561386
#2024-513682-40-01
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
NTRK-1/2/3
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
ROS-1
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
10 recruiting sites
Bristol-Myers Squibb
Phase 3
Lung cancer
#NCT05211895
#2023-506891-28-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Radiotherapy
Excluded genetic anomalies
ALK
EGFR
11 recruiting sites
AstraZeneca
Phase 3
Colon cancer
Rectal cancer
#NCT05253651
#2024-514180-25-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
KRAS G12C
KRAS non G12C
NRAS
18 recruiting sites
Seagen
Phase 3
Breast cancer
#NCT05078047
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced
Metastatic
Required previous treatments at advanced or metastatic stage
Immunotherapy
24 recruiting sites
UNICANCER
Phase 3
Colon cancer
Rectal cancer
#NCT05078047
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MSI/dMMR
Required previous treatments at advanced or metastatic stage
Immunotherapy
24 recruiting sites
UNICANCER
Phase 3
Liver and bile duct cancer
#NCT05078047
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced
Metastatic
Required previous treatments at advanced or metastatic stage
Immunotherapy
24 recruiting sites
UNICANCER
Phase 3
Lung cancer
#NCT06216301
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Non-squamous NSCLC
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
MET
NTRK-1/2/3
RET
ROS-1
8 recruiting sites
NovoCure GmbH
Phase 3
Lung cancer
#NCT05078047
Required disease stage
Locally Advanced
Metastatic
Required previous treatments at advanced or metastatic stage
Immunotherapy
24 recruiting sites
UNICANCER